Animal Vaccines Companies | Market Research Future

Top Industry Leaders in the Animal Vaccines Market

Veterinary Animal Vaccines Key Companies Latest Veterinary/animal vaccines Companies Update

May 2023: The Food and Drug Administration of the United States has approved LibrelaTM (bedinvetmab injectable) for the treatment of osteoarthritis (OA)-related pain in dogs, according to a statement from Zoetis Inc. Librela is the first and only anti-NGF monoclonal antibody medication for canine OA pain that is administered once a month. It has been found to be safe and successful in giving dogs long-term relief from the symptoms of OA pain, which can enhance their mobility and general quality of life. OA discomfort can affect a dog's physical and mental well-being. The inability to climb or descend stairs easily, slow walking speed, reluctance when jumping up and down, limping after exercise, and a tendency to retreat are all indications of OA.

Oct 2023: Boehringer Ingelheim of Germany introduced an unbranded version of its Humira biosimilar, which has a list price of 81% less than the popular rheumatoid arthritis medication made by AbbVie. The business introduced Cyltezo in July, a branded biosimilar drug, at a price 5% less than Humira's current monthly list price of $6,922. Only the close replicas of Humira made by Boehringer can be used instead of the original without contacting a doctor after being given this interchangeability designation by the U.S. Food and Drug Administration. This year, eight Humira biosimilars from businesses, including Sandoz, a division of Novartis, and Amgen, were introduced in the United States. To compete more effectively against Humira and Cyltezo, several businesses also request interchangeability status from the FDA.List of Veterinary/animal vaccines Key companies in the market